flecainide has been researched along with Death, Sudden in 11 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Death, Sudden: The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 9.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 7.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 5.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 5.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 3.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "Many sudden deaths are presumed to be due to an arrhythmia, but the drugs best known for antiarrhythmic activity, the local anesthetic agents, have not been suitable prophylactic agents because of their toxicities and other undesirable pharmacologic characteristics." | 2.65 | Selection of an antiarrhythmic drug for a sudden-death-prevention trial. ( Duff, HJ; Oates, JA; Roden, DM; Woosley, RL, 1982) |
| " If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate." | 1.27 | New directions in antiarrhythmic drug therapy. ( Somberg, JC, 1984) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 1.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Somberg, JC | 1 |
| Woosley, RL | 1 |
| Roden, DM | 1 |
| Duff, HJ | 1 |
| Oates, JA | 1 |
| Reid, PR | 1 |
| Griffith, LS | 1 |
| Platia, EV | 1 |
| Ord, SE | 1 |
| Evers, J | 1 |
| Eichelbaum, M | 1 |
| Kroemer, HK | 1 |
| Fish, FA | 1 |
| Gillette, PC | 1 |
| Benson, DW | 1 |
| Furlanello, F | 1 |
| Farré, J | 1 |
| Brugada, P | 1 |
| Ruskin, JN | 1 |
| Kou, WH | 1 |
| Nelson, SD | 1 |
| Lynch, JJ | 1 |
| Montgomery, DG | 1 |
| DiCarlo, L | 1 |
| Lucchesi, BR | 1 |
| Morganroth, J | 1 |
| Anderson, JL | 1 |
| Gentzkow, GD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Can Global Peak Longitudinal Strain Measurements in Combination With Non-invasive ECG Parameters Predict the Success or Failure of Flecainide Treatment for Atrial Fibrillation Patients?[NCT05084495] | 100 participants (Anticipated) | Observational | 2022-02-01 | Recruiting | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
1 review available for flecainide and Death, Sudden
| Article | Year |
|---|---|
[Postinfarct ventricular extrasystole and the use of anti-arrhythmic drugs: a danger anticipated by electrophysiologists].
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Death, Sudden; Electrophysiology; Flecainide; | 1989 |
3 trials available for flecainide and Death, Sudden
| Article | Year |
|---|---|
Selection of an antiarrhythmic drug for a sudden-death-prevention trial.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1982 |
[Cardiac arrhythmia suppression trial (CAST)].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; Flecainide; H | 1990 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
7 other studies available for flecainide and Death, Sudden
| Article | Year |
|---|---|
New directions in antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benz | 1984 |
Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death.
Topics: Aged; Anti-Arrhythmia Agents; Death, Sudden; Electrocardiography; Female; Flecainide; Hemodynamics; | 1984 |
Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death?
Topics: Aged; Death, Sudden; Dose-Response Relationship, Drug; Female; Flecainide; Humans; Male; Middle Aged | 1994 |
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden; Encainide; Flecainide; | 1991 |
The cardiac arrhythmia suppression trial (CAST).
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Encainide; Flecainide; Humans | 1989 |
Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death.
Topics: Animals; Death, Sudden; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Electric Stimula | 1987 |
Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
Topics: Arrhythmias, Cardiac; Death, Sudden; Drug Administration Schedule; Flecainide; Heart Failure; Humans | 1986 |